These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2842810)

  • 1. Specificity within the GABAA receptor supramolecular complex: a consideration of the new omega 1-receptor selective imidazopyridine hypnotic zolpidem.
    Lloyd KG; Zivkovic B
    Pharmacol Biochem Behav; 1988 Apr; 29(4):781-3. PubMed ID: 2842810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity of zolpidem and other hypnotics within the gamma-aminobutyric acid (GABAA) receptor supramolecular complex, as determined by 35S-t-butylbicyclophosphorothionate (35S-TBPS) binding to rat cerebral cortex membranes.
    Lloyd GK; Danielou G; Thuret F
    J Pharmacol Exp Ther; 1990 Nov; 255(2):690-6. PubMed ID: 2173755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of activities within the GABAA-chloride ionophore complex by means of 35-S-TBPS binding.
    Lloyd KG; Danielou G; Thuret F
    Adv Biochem Psychopharmacol; 1988; 45():199-207. PubMed ID: 2459920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of [35S]TBPS binding by ligands with preferential affinity for benzodiazepine BZ1 sites in the cerebral cortex of newborn and adult rats.
    Giorgi O; Lecca D; Cancedda E; Serra GP; Corda MG
    Eur J Pharmacol; 1995 Jun; 290(1):37-47. PubMed ID: 7664823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes.
    Griebel G; Perrault G; Letang V; Granger P; Avenet P; Schoemaker H; Sanger DJ
    Psychopharmacology (Berl); 1999 Sep; 146(2):205-13. PubMed ID: 10525757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of GABAergic transmission by zolpidem, an imidazopyridine with preferential affinity for type I benzodiazepine receptors.
    Biggio G; Concas A; Corda MG; Serra M
    Eur J Pharmacol; 1989 Feb; 161(2-3):173-80. PubMed ID: 2542044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem.
    Kralic JE; O'Buckley TK; Khisti RT; Hodge CW; Homanics GE; Morrow AL
    Neuropharmacology; 2002 Sep; 43(4):685-94. PubMed ID: 12367614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological profile and clinical effect of zolpidem (Myslee tablets), a hypnotic agent].
    Shirakawa K
    Nihon Yakurigaku Zasshi; 2002 Feb; 119(2):111-8. PubMed ID: 11862759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A specific domain (the omega 1 site) of the GABA(A) receptor may be implicated in the hypnotic effects of zolpidem].
    Benavides J; Depoortere H; Sanger D; Perrault G; Arbilla S; Langer SZ; Zivkovic B; Scatton B
    Encephale; 1990; 16(1):13-22. PubMed ID: 2158421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo interaction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by [3H]Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the omega 1 (BZD1) subtype.
    Benavides J; Peny B; Dubois A; Perrault G; Morel E; Zivkovic B; Scatton B
    J Pharmacol Exp Ther; 1988 Jun; 245(3):1033-41. PubMed ID: 2838599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects.
    Depoortere H; Zivkovic B; Lloyd KG; Sanger DJ; Perrault G; Langer SZ; Bartholini G
    J Pharmacol Exp Ther; 1986 May; 237(2):649-58. PubMed ID: 2871178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors.
    Mereu G; Carcangiu G; Concas A; Passino N; Biggio G
    Eur J Pharmacol; 1990 Apr; 179(3):339-45. PubMed ID: 1973107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics.
    Perrault G; Morel E; Sanger DJ; Zivkovic B
    Eur J Pharmacol; 1990 Oct; 187(3):487-94. PubMed ID: 1981555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of the hypnotic zolpidem in vivo.
    Crestani F; Martin JR; Möhler H; Rudolph U
    Br J Pharmacol; 2000 Dec; 131(7):1251-4. PubMed ID: 11090095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contribution of zolpidem in the management of sleep disorders].
    Lavoisy J; Zivkovic B; Benavides J; Perrault GH; Robert P
    Encephale; 1992; 18(4):379-92. PubMed ID: 1363657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem.
    Sanger DJ; Morel E; Perrault G
    Eur J Pharmacol; 1996 Oct; 313(1-2):35-42. PubMed ID: 8905326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of zolpidem treatment and withdrawal on the in vitro expression of recombinant alpha1beta2gamma2s GABA(A) receptors expressed in HEK 293 cells.
    Vlainić J; Jembrek MJ; Strac DS; Pericić D
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Sep; 382(3):201-12. PubMed ID: 20652804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem.
    Benavides J; Peny B; Ruano D; Vitorica J; Scatton B
    Brain Res; 1993 Feb; 604(1-2):240-50. PubMed ID: 8096157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The behavioral profile of zolpidem, a novel hypnotic drug of imidazopyridine structure.
    Sanger DJ; Perrault G; Morel E; Joly D; Zivkovic B
    Physiol Behav; 1987; 41(3):235-40. PubMed ID: 3324120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vivo and in vitro regional selectivity of central omega (benzodiazepine) site ligands in inhibiting [3H]flumazenil binding in the rat central nervous system.
    Benavides J; Peny B; Durand A; Arbilla S; Scatton B
    J Pharmacol Exp Ther; 1992 Nov; 263(2):884-96. PubMed ID: 1331419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.